FDA Approves Second OTC Naloxone Nasal Spray

Last week, the Food and Drug Administration (FDA) granted approval for the second over-the-counter (OTC) naloxone nasal spray, RiVive. This follows the approval in March of Narcan, the first naloxone product ever approved for use without a prescription. Naloxone is a life-saving medication that can reverse the effects of an illicit fentanyl overdose and prevent deaths when delivered in a timely manner. This approval is crucial in addressing the ongoing opioid crisis as fatal opioid overdoses remain alarmingly high.

ASA continues to strongly support the expansion of equitable access to naloxone to all patients across the United States as a nonprescription treatment and applauds FDA’s leadership in taking action to combat the devasting impact of opioid-related fatalities.